Logo image of NOV.DE

NOVO NORDISK A/S-B (NOV.DE) Stock Price, Quote, News and Overview

FRA:NOV - Deutsche Boerse Ag - DK0062498333 - Common Stock - Currency: EUR

62.24  +1.54 (+2.54%)

NOV.DE Quote, Performance and Key Statistics

NOVO NORDISK A/S-B

FRA:NOV (5/30/2025, 5:28:26 PM)

62.24

+1.54 (+2.54%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High138.48
52 Week Low50.47
Market Cap276.56B
Shares4.44B
Float4.18B
Yearly Dividend1.33
Dividend Yield2.5%
PE19.76
Fwd PE13.98
Earnings (Next)08-06 2025-08-06/bmo
IPO05-17 1974-05-17


NOV.DE short term performance overview.The bars show the price performance of NOV.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30

NOV.DE long term performance overview.The bars show the price performance of NOV.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40

The current stock price of NOV.DE is 62.24 EUR. In the past month the price increased by 2.32%. In the past year, price decreased by -49.85%.

NOVO NORDISK A/S-B / NOV Daily stock chart

NOV.DE Competitors/Peers

The largest stocks on the EU markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY.DE ELI LILLY & CO 53.11 614.04B
1LLY.MI ELI LILLY & CO 52.27 604.37B
ZEG.DE ASTRAZENECA PLC 16.03 385.22B
JNJ.DE JOHNSON & JOHNSON 15.29 327.85B
1JNJ.MI JOHNSON & JOHNSON 15.13 324.34B
RHO.DE ROCHE HOLDING AG-BR 14.72 239.86B
1SAN.MI SANOFI 12.22 228.72B
SNW.DE SANOFI 12.04 225.36B
SAN.PA SANOFI 11.38 213.00B
NOT.DE NOVARTIS AG-REG 13.52 196.32B
1MRKX.MI MERCK & CO. INC. 9.9 171.75B
6MK.DE MERCK & CO. INC. 9.78 169.75B

About NOV.DE

Company Profile

NOV logo image Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Company Info

NOVO NORDISK A/S-B

Novo Alle 1

Bagsvaerd DK

Employees: 76302

NOV Company Website

NOV Investor Relations

Phone: 4544448888

NOVO NORDISK A/S-B / NOV.DE FAQ

What is the stock price of NOVO NORDISK A/S-B today?

The current stock price of NOV.DE is 62.24 EUR. The price increased by 2.54% in the last trading session.


What is the ticker symbol for NOVO NORDISK A/S-B stock?

The exchange symbol of NOVO NORDISK A/S-B is NOV and it is listed on the Deutsche Boerse Ag exchange.


On which exchange is NOV.DE stock listed?

NOV.DE stock is listed on the Deutsche Boerse Ag exchange.


What is the price forecast or stock price prediction for NOVO NORDISK A/S-B stock?

32 analysts have analysed NOV.DE and the average price target is 91.97 EUR. This implies a price increase of 47.77% is expected in the next year compared to the current price of 62.24. Check the NOVO NORDISK A/S-B stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is NOVO NORDISK A/S-B worth?

NOVO NORDISK A/S-B (NOV.DE) has a market capitalization of 276.56B EUR. This makes NOV.DE a Mega Cap stock.


How many employees does NOVO NORDISK A/S-B have?

NOVO NORDISK A/S-B (NOV.DE) currently has 76302 employees.


What are the support and resistance levels for NOVO NORDISK A/S-B (NOV.DE) stock?

NOVO NORDISK A/S-B (NOV.DE) has a support level at 62.06 and a resistance level at 62.25. Check the full technical report for a detailed analysis of NOV.DE support and resistance levels.


Is NOVO NORDISK A/S-B (NOV.DE) expected to grow?

The Revenue of NOVO NORDISK A/S-B (NOV.DE) is expected to grow by 19.4% in the next year. Check the estimates tab for more information on the NOV.DE EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy NOVO NORDISK A/S-B (NOV.DE) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does NOVO NORDISK A/S-B (NOV.DE) stock pay dividends?

NOVO NORDISK A/S-B (NOV.DE) has a dividend yield of 2.5%. The yearly dividend amount is currently 1.33. Check the full fundamental report for a detailed analysis of NOV.DE dividend history, reliability and sustainability.


When does NOVO NORDISK A/S-B (NOV.DE) report earnings?

NOVO NORDISK A/S-B (NOV.DE) will report earnings on 2025-08-06, before the market open.


What is the Price/Earnings (PE) ratio of NOVO NORDISK A/S-B (NOV.DE)?

The PE ratio for NOVO NORDISK A/S-B (NOV.DE) is 19.76. This is based on the reported non-GAAP earnings per share of 3.15 and the current share price of 62.24 EUR. Check the full fundamental report for a full analysis of the valuation metrics for NOV.DE.


NOV.DE Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to NOV.DE. When comparing the yearly performance of all stocks, NOV.DE is a bad performer in the overall market: 96.82% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

NOV.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 7 / 10 to NOV.DE. NOV.DE scores excellent points on both the profitability and health parts. This is a solid base for a good stock.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NOV.DE Financial Highlights

Over the last trailing twelve months NOV.DE reported a non-GAAP Earnings per Share(EPS) of 3.15. The EPS increased by 17.96% compared to the year before.


Industry RankSector Rank
PM (TTM) 34.78%
ROA 21.68%
ROE 70.38%
Debt/Equity 0.62
Chartmill High Growth Momentum
EPS Q2Q%14.96%
Sales Q2Q%19.49%
EPS 1Y (TTM)17.96%
Revenue 1Y (TTM)25.03%

NOV.DE Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 74% to NOV.DE. The Buy consensus is the average rating of analysts ratings from 32 analysts.

For the next year, analysts expect an EPS growth of 19.72% and a revenue growth 19.4% for NOV.DE


Ownership
Inst Owners37.62%
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
Analysts
Analysts74.38
Price Target91.97 (47.77%)
EPS Next Y19.72%
Revenue Next Year19.4%